Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | PRCP | P42785 | 3/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15388846 | 0.95 | NPSR1 (0.56) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL9276821 | 0.95 | NPSR1 (0.56) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL15388843 | 0.95 | NPSR1 (0.56) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL9276825 | 0.95 | NPSR1 (0.56) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL9275048 | 0.95 | NPSR1 (0.56) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL9279791 | 0.95 | NPSR1 (0.56) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL9279782 | 0.95 | NPSR1 (0.56) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL9275043 | 0.95 | NPSR1 (0.56) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL9277170 | 0.93 | NPSR1 (0.57) | NPSR1PRCPNAAAFKBP1APOLB | |
| SCHEMBL9277176 | 0.93 | NPSR1 (0.57) | NPSR1PRCPNAAAFKBP1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193762-B2 | Selective inhibitors of prolylcarboxypeptidase | UNIVERSITY OF MISSISSIPPI (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130310311-A1 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | THE UNIVERSITY OF MISSISSIPPI | 2013-11-21 | — | — | US | disclosed |
| WO-2012075287-A2 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | THE UNIVERSITY OF MISSISSIPPI (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310311-A1 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | PREP, PEPD, DPEP1 | NPSR1 1901/4885PRCP 12/4885NAAA 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.